| scholarly article | Q13442814 |
| P50 | author | Alberto Bardelli | Q28321691 |
| Andrea Sartore-Bianchi | Q28321693 | ||
| Salvatore Siena | Q28321703 | ||
| Silvio Marco Veronese | Q39051644 | ||
| Angelo Vanzulli | Q43295970 | ||
| Emanuele Valtorta | Q57018578 | ||
| A Amatu | Q82728305 | ||
| P2093 | author name string | Rachele Alzani | |
| Antonella Leone | |||
| Jonathan Lim | |||
| Alessio Somaschini | |||
| Antonella Isacchi | |||
| Arturo Galvani | |||
| David Luo | |||
| Elena Ardini | |||
| Giovanna Marrapese | |||
| Roberta Bosotti | |||
| Zachary Hornby | |||
| Marcella Martignoni | |||
| Laura Palmeri | |||
| Sandra Misale | |||
| Erica Bonazzina | |||
| Patrizia Banfi | |||
| Cristina Davite | |||
| Laura Raddrizzani | |||
| P2860 | cites work | Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. | Q27852601 |
| A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences | Q28282360 | ||
| Kinase fusions are frequent in Spitz tumours and spitzoid melanomas | Q33854847 | ||
| The landscape of kinase fusions in cancer | Q34437602 | ||
| Tyrosine kinase gene rearrangements in epithelial malignancies | Q37515966 | ||
| The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. | Q38981486 | ||
| A conserved splicing mechanism of the LMNA gene controls premature aging. | Q45781073 | ||
| Anchored multiplex PCR for targeted next-generation sequencing | Q48254505 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| metastatic colon cancer | Q108566365 | ||
| P577 | publication date | 2015-11-12 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer | |
| P478 | volume | 108 |
| Q90702699 | A systematic review of salvage therapies in refractory metastatic colorectal cancer |
| Q52371842 | Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. |
| Q47113874 | Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy |
| Q64079974 | Antitumor activity of larotrectinib in tumors harboring gene fusions: a short review on the current evidence |
| Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
| Q38891711 | Causes and consequences of nuclear envelope alterations in tumour progression |
| Q55003763 | Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. |
| Q38652194 | Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation |
| Q55306266 | Colorectal cancer genomics and designing rational trials. |
| Q39066439 | Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer |
| Q27853380 | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial |
| Q38941928 | Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer |
| Q91981735 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials |
| Q38800617 | Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model |
| Q90950820 | Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q41548672 | Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient |
| Q46229973 | Identification of NTRK fusions in pediatric mesenchymal tumors |
| Q46044924 | Infantile NTRK-associated Mesenchymal Tumors. |
| Q54981810 | Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. |
| Q103803739 | Mining potentially actionable kinase gene fusions in cancer cell lines with the KuNG FU database |
| Q90250949 | Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis |
| Q37710556 | Molecular Testing for Gastrointestinal Cancer. |
| Q92924197 | NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target |
| Q28066821 | NTRK gene fusions as novel targets of cancer therapy across multiple tumour types |
| Q91620740 | NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases |
| Q58784257 | Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond |
| Q36432094 | Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer |
| Q38794338 | Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications |
| Q58883545 | PATRI, a Genomics Data Integration Tool for Biomarker Discovery |
| Q38956444 | Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions |
| Q38698206 | Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience |
| Q91361623 | Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS |
| Q89529095 | Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges |
| Q36350870 | Promoter hypermethylation as a mechanism for Lamin A/C silencing in a subset of neuroblastoma cells. |
| Q93375221 | Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial |
| Q55289701 | Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. |
| Q64237933 | Refractory and metastatic infantile fibrosarcoma harboring fusion shows complete and durable response to crizotinib |
| Q41636361 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). |
| Q57050736 | TRK Inhibition: A New Tumor-Agnostic Treatment Strategy |
| Q92193162 | The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer |
| Q58799989 | The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer |
| Q55422121 | The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII. |
| Q39166808 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II. |
Search more.